Loading clinical trials...

TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation | Clinical Trials | Clareo Health

RECRUITINGNA

TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation

NCT05521711•Hamilton Health Sciences Corporation

Summary

Tree nut immunotherapy Route Assessment and DEvelopment (TRADE) is a randomized controlled trial that evaluates the efficacy and safety of sublingual immunotherapy and lower, more tolerable, doses of oral immunotherapy than currently in use.

Eligibility

Age

1 - 16 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Allergic to tree nut with baseline threshold of 444 mg protein or less and provides consent, and where applicable, assent.

Exclusion Criteria

•1. History of anaphylaxis to tree nut severe enough to cause shock, syncope, or intubation
•2. Eosinophilic or other inflammatory gastrointestinal disease within the past 2 years
•3. Severe (GINA severity class 5) or uncontrolled asthma including exacerbation within past 6 months
•4. Use of biologics, other food immunotherapy or experimental treatment in past 6 months.
•5. Ongoing other allergic diseases severe enough to preclude discontinuing antihistamines for 7 days prior to assessment visits
•6. Pregnancy or significant medical condition (e.g., liver, kidney, gastrointestinal, cardiovascular, hematologic, or pulmonary disease; allergy to the oat-based placebo) which would put the participant at excessive risk for food allergic reactions as judged by local investigator

Locations (1)

McMaster University Medical Centre

Hamilton, Ontario, Canada

Key Dates

Start Date

September 1, 2023

Primary Completion Date

November 1, 2026

Completion Date

January 1, 2027

Last Updated

June 3, 2024

Enrollment

ESTIMATED participants

Conditions

Tree Nut AllergyFood Allergy

Interventions

Food

OTHER

Contacts

Heather Le

CONTACT

905-521-2100 lehea@hhsc.ca

Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders

NCT00267501

Eosinophilic Gastrointestinal Disease Eosinophilic Inflammatory DiseaseFood Allergy

View study

RECRUITINGNA

Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg

NCT06260956

Allergy and ImmunologyPeanut and Nut Allergy+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 3, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation

Inclusion Criteria

Exclusion Criteria

Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders

Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg

Evaluation of The Food Allergy Mastery Program

Effect of Omalizumab in the Skin of Food Allergy Patients

The NACHO Trial (Nut Allergy Children OIT)

EPAP, Interviewstudy